IMMUNOVACCINE
Immunovaccine Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.
Immunovaccine’s DepoVax™ platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.
